Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (10), 2464-2470
- https://doi.org/10.1038/s41409-021-01364-0
Abstract
Currently, there is no consensus on best practices to prevent hemorrhagic cystitis (HC) in patients receiving posttransplant cyclophosphamide (PTCy). We retrospectively reviewed 194 patients undergoing their first hematopoietic cell transplant (HCT) who received PTCy from 2014 to 2018 to describe the incidence and severity of HC, identify potential risk factors, and impact of HC on HCT outcomes. Standard HC prophylaxis was hyperhydration with forced diuresis and mesna at 320% the daily dose of PTCy. Incidence of HC was 31.4% at day +100 of HCT. Median onset of HC was 12 days with 11.5% grade 3 HC and no Grade 4 HC. Patients with chemical HC experienced earlier onset (7 days vs. 34 days, p < 0.001) with a shorter median resolution time (5 days vs. 14 days, p = 0.001) when compared to BK-associated HC. In multivariate analysis, age above 60 years (HR 4.16, p = 0.006) and myeloablative conditioning (HR 2.44, p = 0.054) were associated with higher risk for HC, but overall, HC did not affect nonrelapse mortality or overall survival. In conclusion, hyperhydration with forced diuresis combined with aggressive mesna dosing is an effective strategy in preventing severe PTCy-associated HC, subsequently preventing any negative impact on transplant outcome.Keywords
This publication has 32 references indexed in Scilit:
- Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation CyclophosphamideScience Translational Medicine, 2013
- BK virus (BKV) plasma dynamics in patients with BKV‐associated hemorrhagic cystitis following allogeneic stem cell transplantationTransplant Infectious Disease, 2013
- BK polyomavirus: emerging pathogenMicrobes and Infection, 2012
- Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II TrialTransplantation and Cellular Therapy, 2012
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseBlood, 2010
- Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor typeHaematologica, 2010
- Cyclophosphamide and cancer: golden anniversaryNature Reviews Clinical Oncology, 2009
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy ProtectantsJournal of Clinical Oncology, 2009
- Polyomavirus BK infection in blood and marrow transplant recipientsBone Marrow Transplantation, 2007
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005